NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Bhat, Rauf ^a   Rommelaere, Jean ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Colon carcinoma; Cytotoxicity; Human natural killer cells; IL 2; Natural cytotoxicty receptors; Oncolytic virus; Parvovirus

Indexed keywords

INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; VIRUS DNA; ONCOLYTIC VIRUS;

ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL ISOLATION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; H-1 PARVOVIRUS; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PARVOVIRUS INFECTION; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; ADENOCARCINOMA; COLON TUMOR; FLOW CYTOMETRY; IMMUNOLOGY; ONCOLYTIC VIROTHERAPY; PROCEDURES; VIROLOGY;

ADENOCARCINOMA; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; H-1 PARVOVIRUS; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PARVOVIRIDAE INFECTIONS;

EID: 84880956694     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-367     Document Type: Article

References (27)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
2. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006, 18(3):151-158. 10.1016/j.smim.2006.03.002, 16730454.
3. Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol 2009, 14:10.
4. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005, 365(9454):153-165. 10.1016/S0140-6736(05)17706-X, 15639298.
5. Evans C, Dalgleish AG, Kumar D. Immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006, 24(8):1163-1177. 10.1111/j.1365-2036.2006.03075.x, 17014575.
6. Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods 1991, 33:233-251. 10.1016/0166-0934(91)90024-T, 1783673.
7. Cotmore SF, Tattersall P. The autonomously replicating parvoviruses of vertebrates. Adv Virus Res 1987, 33:91-174.
8. Faisst S, Schlehofer JR, Zur Hausen H. Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation. J Virol 1989, 63:2152. 250632, 2495371.
9. Malerba M, Daeffler L, Rommelaere J, Iggo RD. Replicating Parvoviruses that target Colon Cancer Cells. J Virol 2003, 77(12):6683-6691. 10.1128/JVI.77.12.6683-6691.2003, 156172, 12767988.
10. Malerba M, Nikolova D, Cornelis J, Iggo R. Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter. Cancer Gene Ther 2006, 13(3):273-280. 10.1038/sj.cgt.7700904, 16151476.
11. Bhat R, Dempe S, Dinsart C, Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer 2011, 128(4):908-919. 10.1002/ijc.25415, 20473905.
12. Wrzesinski C, Tesfay L, Salome N, Jauniaux JC, Rommelaere J, Cornelis J, Dinsart C. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003, 77:3851-3858. 10.1128/JVI.77.6.3851-3858.2003, 149498, 12610161.
13. Cornelis JJ, Spruyt N, Spegelaere P, Guetta E, Darawshi T, Cotmore SF, Tal J, Rommelaere J. Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression. J Virol 1988, 62:3438-3444. 253468, 3404581.
14. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999, 6:973-985. 10.1038/sj.gt.3300938, 10455399.
15. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA 1999, 96(10):5640-5644. 10.1073/pnas.96.10.5640, 21913, 10318937.
16. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6:595-601. 10.1038/nri1901, 16868550.
17. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009, 114(13):2657-2666. 10.1182/blood-2009-01-201632, 2756125, 19628705.
18. Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M, Krönke M, Hallek M, Pogge von Strandmann E. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 2013, 121(18):3658-3665. 10.1182/blood-2013-01-476606, 3643764, 23509156.
19. Pahl JH, Ruslan SE, Kwappenberg KM, Van Ostaijen-Ten Dam MM, Van Tol MJ, Lankester AC, Schilham MW. Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity. Cancer Immunol Immunotherapy 2013, 62(7):1235-1247.
20. Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. Plos One 2007, 2(12):e1339. 10.1371/journal.pone.0001339, 2129109, 18092004.
21. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E, Porgador A, Honigman A, Plachter B, Mevorach D, Wolf DG, Mandelboim O. Inhibition of the NKp30 activating receptor by pp 65 of human cytomegalovirus. Nat Immunol 2005, 6(5):515-523. 10.1038/ni1190, 15821739.
22. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, De Bono J, Selby P, Coffey M, Vile R, Melcher A. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008, 180:6018-6026.
23. Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus. J Immunol 2009, 183(7):4312-4321. 10.4049/jimmunol.0901074, 19734207.
24. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 2005, 16(8):996-1005. 10.1089/hum.2005.16.996, 16076257.
25. Grekova SP, Raykov Z, Zawatzky R, Rommelaere J, Koch U. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection. Cancer Gene Ther 2012, 19(7):468-475. 10.1038/cgt.2012.20, 22539062.
26. Dempe S, Lavie M, Struyf S, Bhat R, Verbeke H, Paschek S, Berghmans N, Geibig R, Rommelaere J, Van Damme J, Dinsart C. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother 2012, 61(11):2113-2123. 10.1007/s00262-012-1279-4, 22576056.
27. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, Garcia KC. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484(7395):529-533. 10.1038/nature10975, 3338870, 22446627.